Treatment of Non-Tuberculous Mycobacterial Lung Disease
Authors:
- 11 October 2016
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 8 (4) , 275-296
Abstract
Opinion statement Treatment of non-tuberculous mycobacterial lung disease (NTM-LD) is challenging for several reasons including the relative resistance of NTM to currently available drugs and the difficulty in tolerating prolonged treatment with multiple drugs. Yet-to-be-done, large, multicenter, prospective randomized studies to establish the best regimens will also be arduous because multiple NTM species are known to cause human lung disease, differences in virulence and response to treatment between different species and strains within a species will make unbias randomization difficult, the need to distinguish relapse from a new infection, and the difficulty in adhering to the prescribed treatment due to intolerance, toxicity, and/or drug-drug interactions, often necessitating modification of therapeutic regimens. Furthermore, the out-of-state resident status of many patients seen at the relatively few centers that care for large number of NTM-LD patients pose logistical issues in monitoring response to treatment. Thus, current treatment regimens for NTM-LD are largely based on small case series, retrospective analyses, and guidelines based on expert opinions. It has been nearly 10 years since the publication of a consensus guideline for the treatment of NTM-LD. This review is a summary of the available evidence on the treatment of the major NTM-LD until more definitive studies and guidelines become available.Keywords
This publication has 116 references indexed in Scilit:
- Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing RegimenAntimicrobial Agents and Chemotherapy, 2013
- In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial DiseaseAntimicrobial Agents and Chemotherapy, 2012
- Multilocus Sequence Analysis and rpoB Sequencing of Mycobacterium abscessus (Sensu Lato) StrainsJournal of Clinical Microbiology, 2011
- Antibiotic Treatment of Mycobacterium abscessus Lung Disease: A Retrospective Analysis of 65 PatientsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Region of Difference 1 in Nontuberculous Mycobacterium Species Adds a Phylogenetic and Taxonomical CharacterJournal of Bacteriology, 2009
- Cohort Study of Molecular Identification and Typing of Mycobacterium abscessus, Mycobacterium massiliense , and Mycobacterium bolletiiJournal of Clinical Microbiology, 2009
- Structural Analysis of Biofilm Formation by Rapidly and Slowly Growing Nontuberculous MycobacteriaApplied and Environmental Microbiology, 2009
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- rpoB sequence-based identification of Mycobacterium avium complex speciesMicrobiology, 2008
- Association between 16S-23S Internal Transcribed Spacer Sequence Groups of Mycobacterium avium Complex and Pulmonary DiseaseJournal of Clinical Microbiology, 2008